Germany’s BioNTech is acquiring Kite’s solid tumor neoantigen T-cell receptor (TCR) research-and-development platform and the Gilead company’s clinical manufacturing plant in Gaithersburg, Maryland.

Three biopharma companies became publicly traded companies and made their debut on the Nasdaq this week.

T-knife GmbH, based in Berlin, Germany, closed a €66 million ($78.4 million) Series A round led by Versant Ventures and RA Capital Management.

At least 10 different drug compounds ranging from cancer therapies to antipsychotics and antihistamines may be effective at preventing the new coronavirus from multiplying in the body, according to a multidisciplinary study conducted by a team of scientists in the United States and France.

Researchers with the Abramson Cancer Center of the University of Pennsylvania, led by Carl June, published results from the first U.S. Phase I trial of CRISPR-Cas9-edited T-cells in humans with advanced cancer.

Researchers at Cardiff University in the UK have essentially identified a new T-cell and its receptor that can search out and kill a broad range of cancer cells.

Adicet Bio Inc., a biopharmaceutical company focused on the development of cancer therapies using gamma delta T cells, raised $80 million in private funding.